ISIN | LU0415392322 |
---|---|
No. de valeur | 3882743 |
Bloomberg Global ID | BBG000JKZJQ6 |
Nom de fond | Bellevue Obesity Solutions B USD |
Prestataire de fonds |
Bellevue Asset Management AG
Zürich, Suisse Téléphone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Prestataire de fonds | Bellevue Asset Management AG |
Représentant en Suisse |
Waystone Fund Services (Switzerland) SA Lausanne Téléphone: 0041213111781 |
Distributeur(s) |
Bank am Bellevue AG Küsnacht Téléphone: +41 44 267 67 67 |
Classe d'actifs | Fonds en actions |
EFC Catégorie | |
Catégorie de parts | Accumulation |
Pays d'origine | Luxembourg |
Conditions d'émission de parts | Frais de transaction en faveur du fonds (participation à la couverture des frais lors du placement de nouvelles ressources entrées) |
Conditions de rachat de parts | Pas de commission de rachat et/ou de taxes en faveur du fonds (le rachat a lieu à la valeur d'inventaire) |
Stratégie d'investissement *** | The investment objective of the fund is to achieve long-term capital growth by investing at least two thirds of the net assets in a portfolio of carefully chosen shares and preference shares of companies whose business is directed towards the prevention and treatment of overweight or obesity and their secondary conditions or companies whose main activity involves holding investments in such companies or financing such companies and that have their registered office or carry out the majority of their economic activity in recognised countries. |
Particularités |
Prix actuel * | 555.90 USD | 13.09.2024 |
---|---|---|
Prix précédent * | 551.48 USD | 09.09.2024 |
Max 52 semaines * | 565.57 USD | 30.08.2024 |
Min 52 semaines * | 450.11 USD | 27.10.2023 |
NAV * | 555.90 USD | 13.09.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Prix minimal indicatif | ||
Actifs du fonds *** | 41'602'437 | |
Actifs de la classe *** | ||
Trading Information SIX |
YTD Performance | +15.55% |
29.12.2023 - 13.09.2024
29.12.2023 13.09.2024 |
---|---|---|
YTD Performance (en CHF) | +16.61% |
29.12.2023 - 13.09.2024
29.12.2023 13.09.2024 |
1 mois | +2.71% |
13.08.2024 - 13.09.2024
13.08.2024 13.09.2024 |
3 mois | +5.37% |
13.06.2024 - 13.09.2024
13.06.2024 13.09.2024 |
6 mois | +7.60% |
14.03.2024 - 13.09.2024
14.03.2024 13.09.2024 |
1 an | +10.42% |
13.09.2023 - 13.09.2024
13.09.2023 13.09.2024 |
2 ans | +9.33% |
13.09.2022 - 13.09.2024
13.09.2022 13.09.2024 |
3 ans | -16.04% |
13.09.2021 - 13.09.2024
13.09.2021 13.09.2024 |
5 ans | +30.16% |
13.09.2019 - 13.09.2024
13.09.2019 13.09.2024 |
Quota de participation de capital en % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Part de la fortune du fonds en % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quota d'immobilier en % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 7.48% | |
---|---|---|
Novo Nordisk A/S Class B | 6.90% | |
UnitedHealth Group Inc | 6.03% | |
Johnson & Johnson | 4.50% | |
Merck & Co Inc | 3.85% | |
Thermo Fisher Scientific Inc | 3.79% | |
Amgen Inc | 3.53% | |
AstraZeneca PLC ADR | 3.33% | |
Regeneron Pharmaceuticals Inc | 3.02% | |
Danaher Corp | 3.00% | |
Dernière mise à jour des données | 31.07.2024 |
TER | 2.26% |
---|---|
Date TER | 01.02.2021 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 1.60% |
Ongoing Charges *** | 2.20% |
SRRI ***
|
|
Date SRRI *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |